Aclaris Therapeutics, Inc.
NASDAQ:ACRS
Overview | Financials
Company Name | Aclaris Therapeutics, Inc. |
Symbol | ACRS |
Currency | USD |
Price | 2.9 |
Market Cap | 207,149,610 |
Dividend Yield | 0% |
52-week-range | 0.856 - 5.17 |
Industry | Diagnostics & Research |
Sector | Healthcare |
CEO | Dr. Douglas J. Manion Frcp(C), M.D. |
Website | https://www.aclaristx.com |
An error occurred while fetching data.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD